1/056/2025 - 1 - Framework agreement for the supply of NILOTINIB PO for Vivalia pharmacies

This tender concerns the establishment of a framework agreement for the supply of NILOTINIB PO (oral administration) for the pharmacies within the Vivalia network. Nilotinib is a targeted therapy medication primarily used to treat chronic myeloid leukemia (CML). The framework agreement aims to ensure a consistent and reliable supply of this critical oncology drug to Vivalia's pharmacies, meeting the treatment needs of patients. The scope includes the procurement and delivery of Nilotinib in the specified oral form. The agreement will likely outline terms for order volumes, delivery schedules, pricing, and quality assurance. The objective is to secure a stable supply chain for this essential medication, ensuring that Vivalia's healthcare facilities can provide uninterrupted treatment to CML patients. This procurement is vital for patient care and treatment continuity within the Vivalia healthcare system.

This is a supplies contract in the health and medical services sector. Located in Belgium, Europe, this opportunity is open to firms and consortiums.

Published through Belgium e-Procurement, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.